3Rs Sharing Conference- Speakers Bios
Laura Andrew, PhD, Vice President of Pharmacology and Toxicology, Genzyme Corporation
Laura Andrews is Vice President of Pharmacology and Toxicology at Genzyme where she directs the nonclinical development programs for biotherapeutics. She is responsible for the nonclinical development programs for therapeutic biologics, gene therapy products, and cell based therapies. Laura oversees the design, implementation and interpretation of the in vivo GLP studies and the in vitro assays to support product development. Laura has authored the pharmacology and toxicology section for several Genzyme INDs and marketing applications in several different territories. Dr. Andrews received a BS (1983) in Biology and Chemistry from Dickinson College, and a Ph.D. (1987) in Pathology and Cell Biology from Thomas Jefferson University and Medical College in Philadelphia, PA. She was Board Certified in General Toxicology in 1998. She holds memberships in the Society of Toxicology (SOT), Society for Toxicologic Pathology (STP) and the American College for Toxicology (ACT). She is vice president-elect for the Biotechnology specialty section within SOT. In addition, she is a member of SACATM (Scientific Advisory Committee on Alternative Toxicological Methods). She has just finished serving on the Board of Directors for the American Board of Toxicology and is a Fellow of the Academy of Toxicologic Sciences.
Ronald P. Hart, PhD,
Rutgers University Cell Biology and Neuroscience
W. M. Keck Center for Collaborative Neuroscience Nelson Lab
Ron Hart is a professor in the department of Cell Biology & Neuroscience at Rutgers University and also a member of the W.M. Keck Center for Collaborative Neuroscience, the Rutgers Stem Cell Research Center, and the Human Genetics Institute of New Jersey. He obtained a B.S. from the University of Connecticut and a Ph.D. from the University of Michigan Medical School. His postdoctoral training was at Rockefeller University. His group studies molecular mechanisms of stem cell differentiation into neurons, focusing on the roles of non-coding RNAs, specific transcription factors, and epigenetic signaling.
Alan M. Hoberman, Ph.D., DABT, Fellow ATS
Executive Director, Site Operations & Toxicology
Preclinical Services, Pennsylvania, Charles River
Dr. Hoberman has been employed by Charles River Laboratories, Preclinical Services, Pennsylvania (formerly Argus Research Laboratories, Inc.) since 1981, serving as Director of Reproductive Toxicology, Director of Research and currently as Executive Director, Site Operations and Toxicology. Prior to joining Argus Research, Dr. Hoberman was the Head of Reproductive Toxicology at Hazleton Laboratories in Vienna, Virginia. He received his BS in Biology from Drexel University, and was a graduate student in Anatomy at the University of Virginia before moving to Arkansas and completing a MS in Interdisciplinary Toxicology from the University of Arkansas and a Ph.D. in Toxicology from Pacific Western University. He is a Diplomat of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences, with over 77 publications and book chapters. He is the co-editor of a book on Pediatric Toxicology to be published in January 2012.
Dr. Hoberman has been a member of the Teratology Society since 1978. He has also been on the council of the European Teratology Society and is Past President of the Reproductive and Developmental Toxicity Specialty Section of the Society of Toxicology of the Middle Atlantic Reproductive and Teratology Association, as well as a member of the Arkansas Biotechnology Organization. He is the Editor of the Journal of Toxicology and Industrial Health and serves on the editorial board of the International Journal of Toxicology. Dr. Hoberman is also the Secretary/Treasurer and a Board Member of the Pennsylvania Society for Biomedical Research.
Jennifer Houston, BA, RVT, LATG
Clinical Education Specialist at ETHICON, a Johnson & Johnson Company
Jenny Houston has a research background in industry and academia, having experience in animal husbandry at Procter & Gamble and ophthalmology research at the University of Texas Southwestern Medical Center. Since 2005, Ms. Houston has been a Clinical Education Specialist at Ethicon, part of the Johnson & Johnson family of companies. She has been heavily involved with educating and demonstrating the safe and effective use of surgical devices to medical professionals from around the world. Ms. Houston is Ethicon certified on the science of tissue management for energy and stapling products. Using insight and understanding gained from interacting daily with physicians, nurses, first assistants, administrators and others, she has been instrumental in developing alternatives to animals for hands-on training. These alternatives have been accepted by the medical establishment as being effective and innovative and have strongly contributed to deeper understanding of tissue/device interaction.
Joan Krakowsky, PhD, BioSciences Consultant
Joan Krakowsky is currently a consultant in Biomedical Sciences, specializing in Genetically Modified Animal Models and Pre-clinical Research. Joan received her doctorate in Biomedical Sciences at Wright State University Medical School. She learned to make transgenic animal models during her post-doctoral fellowship at Columbia University in Frank Costantini’s laboratory. After leaving Columbia, Joan set up transgenic animal facilities for University of Cincinnati Medical Center and for Marion Merrill Dow in Cincinnati, Ohio. She worked in the pharmaceutical industry for 18 years making and studying transgenic animals and studying gene expression utilizing a variety of technologies. In 2005, Joan joined the Department of Laboratory Animal Science and Welfare as the Head of Genetically Engineered Mouse Models at Sanofi-Aventis, U.S. (a successor company of Marion Merrill Dow). In 2010, her job expanded and she became responsible for all out-sourced work related to GEMM research, globally. She joined Taconic in 2011 as Associate Director of Commercial Scientific Development and left that position at the end of 2012.
Margaret Landi, VMD, MS, Diplomate ACLAM
Chief of Animal Welfare, Ethics & Strategy, GlaxoSmithKline
Margaret is the Chief of Animal Welfare, Ethics and Strategy for GlaxoSmithKline. Her career started in clinical veterinary medicine. Margaret has been President of the American College of Laboratory Animal Medicine; she has served on the Council of the Institute of Laboratory Animal Research (ILAR) as Editor-in-Chief of the ILAR Journal. Margaret is currently on a number of boards including Chimp Haven.
Margaret has worked internationally over the past decade. Her most recent area of work is in the application of global principles for laboratory animals in an international arena with differing laws, cultures, regulations and policies.
Jan Lund Ottesen, DVM, PhD, DipECLAM, Vice President, Laboratory Animal Science, Novo Nordisk A/S
Jan graduated from the Royal Veterinary and Agriculture Uni¬versity, Copenhagen, Denmark in 1988 and defended his PhD thesis “Transgenic animals – Embryo technological aspects and applications” same place in 1997. Jan has worked for Novo Nordisk 24 years.
Jan is also:
• ECLAM diplomate
• Appointed industry member of Danish Consensus Platform for 3R Alternatives to Animal Experimentation (Dacopa)
• Chair of the Danish Pharmaceutical Industry’s Experimental Animal topic group
• Member of EFPIA (The European Federation of Pharmaceutical Industries and Associations) Research Animal Welfare group
• Member of Novo Nordisk R&D Bioethics Council
Stephen Wilson, Research Scientist II, Charles River Preclinical Services, Nevada
Stephen Wilson joined Charles River in 2001 and has extensive technical skills in discovery pharmacology and surgical models. He serves as a study director with leadership responsibilities in pharmacology, safety pharmacology and general toxicology studies. His scientific expertise spans multiple therapeutic areas, with a focus on cardiovascular and pulmonary function.
He is the author of more than 300 preclinical testing reports and is also an active member of the Safety Pharmacology Society and Pulmonary Research Group. Stephen received his Bachelor of Arts in Biology from the University of San Diego.
Patricia A. Zane, Ph.D., Sanofi US, Bridgewater NJ
Dr. Zane is an Associate Director in the Projects, Standards and Innovations group of Drug Disposition within DSAR at Sanofi. In this role she supports the innovations initiatives in DBS Technology, biopharmaceutics strategies for development of orally administered compounds, Due Diligence activities for in-licensing candidates, and expert support for nonclinical ADME activities. She received her Ph.D. from the University of Medicine and Dentistry of NJ in 1988 on “The Influence of Dose on the Pharmacokinetics of Benzo(a)pyrene in Mice” and did her postdoctoral work at the former Ciba Geigy, Ardsley NY on the physicochemical modeling of tissue distribution of 27 compounds using quantitative whole-body autoradiography, multiple linear regression and molecular modeling. She has held positions at Berlex laboratories (now Bayer) writing registration documents for both small and large molecules as well as support for imaging agents and radiopharmaceuticals. Prior to this she spent 11+ years at Novartis Pharmaceuticals conducting nonclinical discovery and development pharmacokinetics and ADME. She was a founding member of the Society for Whole-body Autoradiography in the US and held positions of Secretary and Treasurer over the period of 1996 to 2003. She is currently Councilor. During her tenure as Secretary, she was responsible for the organization of the first Short Course for Whole-body Autoradiography in the US.